{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "Amount",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ00898",
      "entity_text" : "F1.2",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false,
    "context" : {
      "TissueType" : [ "tissuelist:TS-0803" ],
      "Species" : [ "taxonomy:9606" ]
    }
  },
  "verbose_text" : "XREF_BIBR Furthermore, rivaroxaban treatment has been associated with reductions in D-dimer, TAT, and F1.2 levels in treatment-naive patients with AF, XREF_BIBR XREF_BIBR suggesting that it is possible that at least some of the effects of rivaroxaban on these biomarkers in the current study are mediated by anticoagulant effects.",
  "reading_complete" : "2020-08-02T12:47:38Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-02T12:42:14Z",
  "trigger" : "levels",
  "evidence" : [ "F1.2 levels" ],
  "pmc_id" : "6978177",
  "score" : 0
}